AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 82 filers reported holding AVADEL PHARMACEUTICALS PLC in Q3 2020. The put-call ratio across all filers is 0.74 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,501,683 | -40.8% | 437,056 | -5.2% | 0.00% | -100.0% |
| Q2 2023 | $7,598,840 | +140.0% | 461,094 | +33.4% | 0.00% | – |
| Q1 2023 | $3,166,714 | +27.3% | 345,711 | -0.5% | 0.00% | – |
| Q4 2022 | $2,486,811 | +43.1% | 347,320 | +0.1% | 0.00% | – |
| Q3 2022 | $1,738,000 | +125.1% | 346,852 | +9.6% | 0.00% | – |
| Q2 2022 | $772,000 | -67.1% | 316,361 | -7.8% | 0.00% | – |
| Q1 2022 | $2,343,000 | -36.6% | 343,009 | -25.0% | 0.00% | – |
| Q4 2021 | $3,694,000 | -11.1% | 457,264 | +7.8% | 0.00% | -100.0% |
| Q3 2021 | $4,157,000 | +64.1% | 424,220 | +12.7% | 0.00% | – |
| Q2 2021 | $2,533,000 | +25.0% | 376,265 | +67.9% | 0.00% | – |
| Q1 2021 | $2,026,000 | +39.0% | 224,079 | +2.6% | 0.00% | – |
| Q4 2020 | $1,458,000 | -13.0% | 218,305 | -34.3% | 0.00% | – |
| Q3 2020 | $1,676,000 | +45.1% | 332,466 | +132.6% | 0.00% | – |
| Q2 2020 | $1,155,000 | -12.1% | 142,916 | -13.7% | 0.00% | – |
| Q1 2020 | $1,314,000 | -76.1% | 165,588 | -77.3% | 0.00% | -100.0% |
| Q4 2019 | $5,507,000 | +78.7% | 729,289 | -1.5% | 0.00% | 0.0% |
| Q3 2019 | $3,081,000 | +48.5% | 740,496 | +3.1% | 0.00% | 0.0% |
| Q2 2019 | $2,075,000 | +102.2% | 717,901 | +0.7% | 0.00% | – |
| Q1 2019 | $1,026,000 | -44.9% | 712,658 | -1.3% | 0.00% | -100.0% |
| Q4 2018 | $1,863,000 | -45.4% | 722,019 | -7.1% | 0.00% | 0.0% |
| Q3 2018 | $3,412,000 | +15.4% | 777,272 | +61.2% | 0.00% | 0.0% |
| Q2 2018 | $2,956,000 | -64.2% | 482,236 | -57.4% | 0.00% | -50.0% |
| Q1 2018 | $8,248,000 | -35.6% | 1,131,337 | -27.5% | 0.00% | -50.0% |
| Q4 2017 | $12,798,000 | -18.9% | 1,560,739 | +3.9% | 0.00% | -20.0% |
| Q3 2017 | $15,776,000 | -9.0% | 1,502,426 | -4.4% | 0.01% | 0.0% |
| Q2 2017 | $17,334,000 | -30.7% | 1,571,497 | -39.2% | 0.01% | +25.0% |
| Q1 2017 | $25,022,000 | – | 2,584,892 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WEALTH EFFECTS LLC | 2,305,017 | $18,625,000 | 7.73% |
| COWEN AND COMPANY, LLC | 3,732,778 | $30,161,000 | 2.74% |
| GENDELL JEFFREY L | 2,446,299 | $19,766,000 | 1.60% |
| Asymmetry Capital Management, L.P. | 369,134 | $2,983,000 | 1.58% |
| Vivo Capital, LLC | 2,937,093 | $23,732,000 | 1.43% |
| Samsara BioCapital, LLC | 659,409 | $5,328,000 | 1.03% |
| Altium Capital Management LP | 440,589 | $3,560,000 | 0.98% |
| Knott David M Jr | 258,198 | $2,086,000 | 0.71% |
| RTW INVESTMENTS, LP | 5,741,939 | $46,395,000 | 0.68% |
| FRAZIER MANAGEMENT LLC | 951,814 | $7,691,000 | 0.59% |